Use of a GH receptor antagonist (GHRA) to explore the relationship between GH and IGF-I in adults with severe GH deficiency (GHD)

Clinical Endocrinology

Volumn 70, Issue 3, 2009, Pages 439-445

  Berg, C A ^a   Pokrajac, A ^a   Bidlingmaier, M ^b   Strasburger, C J ^c   Shalet, S M ^a   Trainer, P J ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; GROWTH HORMONE; PEGVISOMANT; PLACEBO; SOMATOMEDIN C;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

ADULT; BODY COMPOSITION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GROWTH DISORDERS; GROWTH HORMONE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; RECEPTORS, SOMATOTROPIN;

EID: 60349122807     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03481.x     Document Type: Article

References (36)

1. Svensson, J., Johannsson, G. Bengtsson, B.A. (1997) Insulin-like growth factor-I in growth hormone-deficient adults: relationship to population-based normal values, body composition and insulin tolerance test. Clinical Endocrinology, 46, 579 586.
2. Veldhuis, J.D. (1996) Gender differences in secretory activity of the human somatotropic (growth hormone) axis. European Journal of Endocrinology, 134, 287 295.
3. Gleeson, H.K., Lissett, C.A. Shalet, S.M. (2005) Insulin-Like Growth Factor-I Response to a Single Bolus of Growth Hormone Is Increased in Obesity. Journal of Clinical Endocrinology and Metabolism, 90, 1061 1067.
4. Copeland, K.C., Colletti, R.B., Devlin, J.T. et al. (1990) The relationship between insulin-like growth factor-I, adiposity, and aging. Metabolism, 39, 584 587.
5. Rasmussen, M.H., Ho, K.K., Kjems, L. et al. (1996) Serum growth hormone-binding protein in obesity: effect of a short-term, very low calorie diet and diet-induced weight loss. Journal of Clinical Endocrinology and Metabolism, 81, 1519 1524.
6. Ho, K.Y., Veldhuis, J.D., Johnson, M.L. et al. (1988) Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. Journal of Clinical Investigation, 81, 968 975.
7. Maccario, M., Aimaretti, G., Grottoli, S. et al. (2001) Effects of 36 hour fasting on GH/IGF-I axis and metabolic parameters in patients with simple obesity. Comparison with normal subjects and hypopituitary patients with severe GH deficiency. International Journal of Obesity-Related Metabolic Disorders, 25, 1233 1239.
8. Darzy, K.H., Murray, R.D., Gleeson, H.K. et al. (2006) The impact of short-term fasting on the dynamics of 24-hour growth hormone (GH) secretion in patients with severe radiation-induced GH deficiency. Journal of Clinical Endocrinology and Metabolism, 91, 987 994.
9. Bates, J.A., Van't Hoff, W., Jones, P.J. et al. (1996) The effect of hypopituitarism on life expectancy. Journal of Clinical Endocrinology and Metabolism, 81, 1169 1172.
10. Rosen, T. Bengtsson, B.-A. (1990) Premature mortality due to cardiovascular disease in hypopituitarism. Lancet, 336, 285 288.
11. Tomlinson, J.W., Holden, N., Hills, R.K. et al. (2001) Association between premature mortality and hypopituitarism. West midlands prospective hypopituitary study group. Lancet, 357, 425 431.
12. Gibney, J., Wallace, J.D., Spinks, T. et al. (1999) The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. Journal of Clinical Endocrinology and Metabolism, 84, 2596 2602.
13. Gotherstrom, G., Svensson, J., Koranyi, J. et al. (2001) A prospective study of 5 years of GH replacement therapy in GH deficient adults: sustained effects on body composition, bone mass, and the metabolic indices. Journal of Clinical Endocrinology and Metabolism, 86, 4657 4665.
14. Florakis, D., Hung, V., Kaltsas, G. et al. (2000) Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study. Clinical Endocrinology, 53, 453 459.
15. Aimaretti, G., Ambrosio, M.R., Di Somma, C. et al. (2004) Traumatic brain injury and subarachnoid haemorrhage are conditions at high risk for hypopituitarism: screening study at 3 months after the brain injury. Clinical Endocrinology, 61, 320 326.
16. No authors listed (1998) Consensus Guidelines for the Diagnosis and Treatment of Adults with Growth Hormone Deficiency: Summary Statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism, 83, 379 381.
17. Mukherjee, A., Monson, J.P., Jonsson, P.J. et al. (2003) Seeking the optimal target range for insulin-like growth factor I during the treatment of adult growth hormone disorders. Journal of Clinical Endocrinology and Metabolism, 88, 5865 5870.
18. Van der Lely, A.J., Hutson, R.K., Trainer, P.J. et al. (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet, 358, 1754 1759.
19. Strasburger, C.J. Kohen, F. (1990) Two-site and competitive chemiluminescent immunoassays. Methods Enzymology, 184, 481 496.
20. Thorner, M.O., Strasburger, C.J., Wu, Z. et al. (1999) Growth hormone (GH) receptor blocade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not actually stimulate serum GH. Journal of Clinical Endocrinology and Metabolism, 84, 2098 2103.
21. Carlsson, L.M., Rowland, A.M., Clark, R.G. et al. (1991) Ligand mediated immunofunctional assay for quantification of growth hormone-binding protein in human blood. Journal of Clinical Endocrinology and Metabolism, 73, 1216 1223.
22. Brabant, G., Von zur Muhlen, Wuster, C. et al. (2003) Serum insulin-like growth factor-I reference values for an automated chemiluminiscence immunoassay system: results from a multicenter study. Hormone Research, 60 (Suppl. 2 53 60.
23. Formica, C.A. (1998) Standardization of BMD measurements. Osteoporos International, 8 1 3.
24. Veldhuis, J.D., Bidlingmaier, M., Anderson, S.M. et al. (2001) Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men. Journal of Clinical Endocrinology and Metabolism, 86, 3304 3310.
25. Brabant, G., Krogh Rasmussen, A., Biller, B.M. et al. (2007) Clinical implications of residual growth hormone (GH) response to provocative testing in adults with severe GH deficiency. Journal of Clinical Endocrinology and Metabolism, 92, 2604 2609.
26. Yin, D., Vreeland, F., Shaaf, L.J. et al. (2007) Clinical pharmacodynamic effect of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clinical Cancer Research, 13, 1000 1009.
27. Harrela, M., Koistinen, H., Kaprio, J. et al. (1996) Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. Journal of Clinical Investigation, 98, 2612 2615.
28. Jones, J.I. Clemmons, D.R. (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocrine Review, 16, 3 34.
29. Rajaram, S., Baylink, D.J. Mohan, S. (1997) Insulin-like growth factor binding proteins in serum and other biological fluids: regulation and functions. Endocrine Review, 18, 801 831.
30. Hwa, V., Oh, Y. Rosenfeld, R.G. (1999) The insulin-like growth factor binding protein (IGFBP) superfamily. Endocrine Review, 20, 761 787.
31. De Boer, H., Blok, G.J., Popp-Snijders, C. et al. (1996) Monitoring of growth hormone replacement therapy in adults based on measurement of serum markers. Journal of Clinical Endocrinology and Metabolism, 81, 1371 1377.
32. Aguiar-Oliveira, M.H., de Gill, M.S.A., Barretto, E.S. et al. (1999) Effect of severe growth hormone (GH) deficiency due to a mutation in the GH-releasing hormone receptor on insulin-like growth factors (IGFs), IGF-binding proteins, and ternary complex formation throughout life. Journal of Clinical Endocrinology and Metabolism, 84, 4118 4126.
33. Páramo, C., Fluiters, E., de la Fuente, J. et al. (2001) Monitoring of treatment success in patients with acromegaly: the value of serum insulin-like growth factor binding protein-3 and serum leptin measurements in comparison to plasma insulin-like growth factor I determination. Metabolism, 50, 1117 1121.
34. Zhang, Y., Jiang, J., Black, R.A. et al. (2000) Tumor necrosis factor-α converting enzyme (TACE) is a GHBP sheddase: the metalloprotease TACE/ADAM-17 is critical for (PMA-induced) GH receptor proteolysis and GHBP generation. Endocrinology, 141, 4342 4348.
35. Katsumata, N. (2005) Growth hormone-binding protein (GHBP). Nippon Rinsho, 63 (Suppl. 8 183 185.
36. Ross, R.J.M., Leung, K.C., Maamra, M. et al. (2001) Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimmer. Journal of Clinical Endocrinology and Metabolism, 86, 1716 1723.